Humulin M3 (Insulin Human (Rdna))

Humulin M3 is indicated for the treatment of diabetes mellitus where both basal and prandial insulin coverage are required.

• Type 1 diabetes mellitus in adults and children requiring mixed insulin therapy.
• Type 2 diabetes mellitus when oral agents and basal insulin alone do not achieve glycemic targets.
• Adjunct to diet and exercise for patients needing predictable post‑meal glucose control.
• Situations where a single daily injection simplifies the regimen compared with separate regular and NPH doses.
• Hospitalized patients who need a stable insulin profile during transition to home therapy.

• Humulin M3 delivers two insulin components that bind to insulin receptors on muscle, adipose and hepatic cells. The regular insulin component rapidly activates the receptor, promoting translocation of GLUT‑4 transporters and increasing glucose uptake within minutes. The NPH component provides a prolonged activation, sustaining receptor signaling and suppressing hepatic gluconeogenesis for up to 12–18 hours. Together they normalize plasma glucose by enhancing peripheral utilization and reducing endogenous glucose production.

The safety profile of Humulin M3 includes a range of adverse reactions that vary in frequency and severity.

Common

• Mild to moderate hypoglycemia, often presenting with sweating, tremor, visual changes, confusion, or brief loss of consciousness.
• Local injection‑site reactions such as redness, swelling, itching or mild pain that usually resolve without treatment.
• Lipodystrophy, including localized lipoatrophy (fat loss) or lipohypertrophy (fat accumulation) at sites of repeated subcutaneous injections.

Serious

• Severe hypoglycemia that necessitates assistance from another person, emergency medical care, or hospitalization.
• Allergic reactions ranging from urticaria and angio‑edema to life‑threatening anaphylaxis.
• Persistent peripheral edema or unexplained electrolyte abnormalities such as hypokalemia that may require clinical evaluation.

When prescribing or using Humulin M3, several precautionary measures should be considered to minimize risks and ensure safe therapy.

• Assess renal and hepatic function before initiating therapy, as impairment can alter insulin clearance.
• Adjust dose in patients with fluctuating dietary intake, physical activity, or concurrent illness.
• Monitor blood glucose closely during pregnancy, although safety data are limited.
• Educate patients on proper injection technique to reduce lipodystrophy and hypoglycemia risk.
• Review concomitant medications that may mask hypoglycemia symptoms, such as beta‑blockers.
• Store the product according to label instructions and discard after the recommended in‑use period.

Humulin M3 may interact with other agents that affect glucose homeostasis or insulin pharmacokinetics.

Avoid

• Concurrent use of other rapid‑acting insulins or premixed insulin products without dose adjustment.
• High‑dose corticosteroids that markedly increase blood glucose levels.

Use with caution

• Beta‑blockers, which can blunt hypoglycemia warning signs.
• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycemia risk.
• Diuretics or ACE inhibitors that may affect potassium balance.
• Alcohol consumption, which can cause delayed hypoglycemia.